Compare BridgeBio Pharma Inc (BBIO) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nike Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nike Inc trades at $41.26 (market cap $62.47B). The key difference: Nike Inc is far larger — about 3.8× BridgeBio Pharma Inc's market cap, and Nike Inc pays a 3.89% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NKE | |
|---|---|---|
Market Cap | $16.61B | $62.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $79.17 |
52-Week Low | $47.29 | $40.75 |
Enterprise Value | $18.16B | $64.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Nike (NKE) trades at $41.32, down 0.91% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong profitability with a 42.91% gross margin and 22.14% ROE, but revenue declined to $46.31B in 2025. Recent quarters have consistently beaten EPS estimates, with Q1 2026 EPS of $0.72 significantly exceeding expectations. Analysts maintain a consensus Buy rating with a $50.45 price target, indicating potential upside from current levels.
The outlook balances solid brand strength and earnings beats against revenue headwinds and competitive pressures. Investment opportunity lies in valuation discount to analyst targets and operational discipline, but risks include sluggish demand in key markets like China and margin compression from promotional activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
